ENZYCHEM LIFESCIENCES CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,880 KRW | +0.70% |
|
+6.88% | +3.41% |
| 05/04 | Enzychem Lifesciences Corporation announces an Equity Buyback for KRW 10,000 million worth of its shares. | CI |
| 05/04 | Enzychem Lifesciences Corporation authorizes a Buyback Plan. | CI |
| Sales 2022 | 26.64B 19.37M 1.61B | Sales 2023 | 76.04B 55.28M 4.61B | Capitalization | 155B 112M 9.37B |
|---|---|---|---|---|---|
| Net income 2022 | -25.09B -18.24M -1.52B | Net income 2023 | -9.33B -6.78M -565M | EV / Sales 2022 | -0.58 x |
| Net cash position 2022 | 155B 113M 9.39B | Net cash position 2023 | 132B 95.74M 7.98B | EV / Sales 2023 | 0.3 x |
| P/E ratio 2022 |
-5.24
x | P/E ratio 2023 |
-16.5
x | Employees | 113 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 87.68% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.70% | ||
| 1 week | +6.88% | ||
| Current month | -0.16% | ||
| 1 month | -7.16% | ||
| 3 months | +9.81% | ||
| 6 months | +66.22% | ||
| Current year | +3.41% |
1 week
1 755.00
1 884.00
1 month
1 699.002 035.00
Current year
1 564.002 080.00
1 year
1 110.002 080.00
3 years
1 110.0024 233.33
5 years
1 110.0030 816.67
10 years
1 110.0030 816.67
| Managers | Title | Age | Since |
|---|---|---|---|
Gi-Young Sohn
CEO | Chief Executive Officer | 62 | 01/12/01 |
Do-Hyeon Jo
COO | Chief Operating Officer | 49 | 21/16/21 |
Myung-Hwan Kim
BRD | Director/Board Member | 67 | 01/15/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gi-Young Sohn
CEO | Chief Executive Officer | 62 | 01/12/01 |
Hye-Kyung Kim
BRD | Director/Board Member | 66 | 01/12/01 |
Jae-Yong Lee
BRD | Director/Board Member | 62 | 01/11/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1,880 | +0.70% | 242,198 |
| 25/24/25 | 1,867 | -0.05% | 367,579 |
| 24/24/24 | 1,868 | +0.97% | 415,059 |
| 23/24/23 | 1,850 | +3.35% | 556,693 |
| 22/24/22 | 1,790 | +1.76% | 365,796 |
End-of-day quote Korea S.E., April 26, 2024
More quotes
ENZYCHEM LIFESCIENCES CORPORATION is a Korea-based Company mainly engaged in the development and manufacture of medical raw materials. The Company provides D-cycloserine, a synthetic product utilizing chiral technology to treat tuberculosis; antibiotics, such as terizidone, cefbuperazone, cefazedone and others; magnetic resonance imaging (MRI) contrast agents such as gadoterate and gadopentate; others for antithrombotic drugs, antiinflammatory analgesic drugs, and drugs for gastric ulcer and hyperlipidemia. The Company also provides functional health food and finished drug products.
Sector
Pharmaceuticals
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +3.41% | 116M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- A183490 Stock
